Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy

By: via Benzinga
The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.